- Previous Close
992.00 - Open
991.00 - Bid 1,003.00 x --
- Ask 1,004.00 x --
- Day's Range
972.00 - 1,010.00 - 52 Week Range
797.00 - 1,763.00 - Volume
24,865 - Avg. Volume
135,375 - Market Cap (intraday)
31.073B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ChoA Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea. The company produces approximately 200 medicines and health foods, including 30 internal ampoule products, such as Hepos, Fematin, Vasoclean, Mabis, etc. Its products include drugs for digestive, circulatory, and respiratory systems; vitamins, minerals, and nutrients; anti inflammation and analgesics; peripheral nervous system; gynecologic diseases; antibiotics, antigens, and anthelmintic; and antitumor, as well as other metabolite medicines. The company offers its products in the form of tablets, capsules, granules, syrups, solutions, drinkable ampoules, and sachets. It also provides medicine supply and pharmacy management services. The company exports its products to approximately 20 countries worldwide. The company was founded in 1964 and is headquartered in Seoul, South Korea.
www.choa.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 034940.KQ
View MorePerformance Overview: 034940.KQ
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 034940.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 034940.KQ
View MoreValuation Measures
Market Cap
31.07B
Enterprise Value
50.31B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.50
Price/Book (mrq)
0.99
Enterprise Value/Revenue
0.80
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-15.32%
Return on Assets (ttm)
-8.44%
Return on Equity (ttm)
-30.21%
Revenue (ttm)
62.69B
Net Income Avi to Common (ttm)
-9.6B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
5.45B
Total Debt/Equity (mrq)
86.44%
Levered Free Cash Flow (ttm)
-894.16M